進口代理─阿根廷─INSTITUTO BIOLÓGICO ARGENTINO 藥品

With more than a hundred years of experience, Instituto Biológico Argentino was the first manufacturing plant in Florencio Varela, province of Buenos Aires. The company manufactures and sells pharmaceutical products, specializing in injectables, semisolids and biological products. 

Its manufacturing site produces injectables (ampules, vials, and carpules), semisolids (ovules and suppositories), and biological APIs (Active Pharmaceutical Ingredients), including serums and antitoxins. The injectables sector has a monthly production capacity of more than 3 million units of ampules and carpules, not only meeting the demand for its own products both in the national and international markets but also supplying other pharmaceutical companies. 

INTI worked on adapting an analytical methodology to test one of its gynecology products, which allowed the company to comply with the product launch plan. 

The manufacturing site includes a formulation and filling facility for injectables consisting of two sterile areas, a segregated plant for manufacturing biological APIs, and a site for producing semisolids. At present, the roofed area is 4,637 m2 in a 60,000 m2 industrial site. 

The company meets the GMP requirements—a set of guidelines that ensure manufacturing standards, as issued by the National Administration of Drugs, Foods and Medical Devices (ANMAT). 

"We consider our customers as ‘business partners’ in their own country, and we work hard to develop a high quality and accessible export offer to meet their needs. Being a medium-sized company gives us the flexibility to adapt our products. Our communication approach is very efficient, so we are able to understand how each market works in order to develop appropriate solutions. We offer differentiated products and have few regional competitors, especially in the biologics market,” remarks Silvana Figueredo, International Business manager. 

The company has designed a traditional export model. More than 30 years ago, it began exporting to the neighboring countries of Bolivia and Paraguay, to later enter new markets such as Peru, Ecuador, Chile, and Uruguay. In 2000, the company began to develop a special formulation of Central American anti-ophidic serum, which made it possible to develop an ideal product for Nicaragua, Honduras, Guatemala, and Panama. Today, it reaches 18 countries, including Georgia, Azerbaijan, and Uzbekistan, and is working towards obtaining a license to ship its products to other countries from the Commonwealth of Independent States. It has also pioneered the export of services, making biological evaluations of its biotherium for foreign companies. It currently expects to reach new markets in the Persian Gulf and other Asian countries. 

In 2020, the organization was awarded the “Mejor práctica frente al COVID-19” (Best Practice against COVID-19) prize, granted by the Economic Federation of the Province of Buenos Aires (FEBA), through its Women Entrepreneurs (ME-FEBA) branch, in the fifth edition of the “Mujer Empresaria Bonaerense” award. 

"We are an ever-growing company; our trustworthiness is built on a longstanding track record, and our motivation is driven by the future. We are always looking for new challenges, bringing reliable and quality products to the medical staff and, at the same time, accessible solutions to patients. 

The development of the international business involves the whole organization and we are aware that we must make our contribution to attain the best results,” Ms. Figueredo concludes. 

● HS CODE (NCM): 

-3004.90.49.900J / Labetalol 

-3004.39.29.900M / Vasopressin 

-3004.90.69.990H / Etomidate/Dexmedetomidine 

-3004.39.29.900M / Gasterin 

-3004.39.99.000G / Noradrenalin 

-3002.12.11.000U / Anti-ophidic Serum

 -3004.20.69.900E / Vagilen

 -3004.20.99.900J / Front 2